CG Oncology, Inc. (NASDAQ:CGON) Receives $61.42 Consensus Target Price from Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $65.5833.

A number of brokerages have recently weighed in on CGON. JPMorgan Chase & Co. raised their price objective on shares of CG Oncology from $41.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, September 26th. Wall Street Zen upgraded CG Oncology from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Truist Financial upped their price objective on CG Oncology from $62.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley set a $93.00 price objective on CG Oncology in a report on Friday. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $82.00 target price on shares of CG Oncology in a research report on Monday.

Insider Activity at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. Additional details regarding this sale are available in the official SEC disclosure.

Institutional Trading of CG Oncology

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after buying an additional 670,770 shares during the period. Wellington Management Group LLP grew its position in CG Oncology by 190.3% during the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after acquiring an additional 3,613,885 shares during the period. Alliancebernstein L.P. raised its position in CG Oncology by 15.0% in the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after purchasing an additional 281,637 shares during the period. Bank of America Corp DE boosted its stake in shares of CG Oncology by 409.9% in the second quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after purchasing an additional 1,396,170 shares during the period. Finally, Franklin Resources Inc. increased its holdings in CG Oncology by 12.7% during the 2nd quarter. Franklin Resources Inc. now owns 1,486,839 shares of the company’s stock worth $38,658,000 after purchasing an additional 167,905 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Stock Performance

Shares of CGON opened at $52.58 on Friday. The stock has a market capitalization of $4.24 billion, a PE ratio of -25.77 and a beta of 1.35. CG Oncology has a 1 year low of $14.80 and a 1 year high of $57.40. The company’s 50-day simple moving average is $41.90 and its 200-day simple moving average is $35.80.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.57). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.07 million. On average, sell-side analysts predict that CG Oncology will post -1.31 earnings per share for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.